OrthoPediatrics Rises to Zacks Rank #2 after 7.8% EPS Revision and 32.7% Upside
OrthoPediatrics received a Zacks Rank #2 upgrade after a 7.8% rise in its consensus EPS estimate over three months, placing it among the top 20% of covered stocks. Analysts’ average price target implies a 32.7% upside for the stock, reflecting bullish sentiment on OrthoPediatrics shares.
1. Zacks Rank Upgrade
OrthoPediatrics was elevated to Zacks Rank #2, placing it within the top 20% of all covered stocks based on its earnings estimate momentum. This upgrade signals a notable improvement in the company’s near-term earnings outlook.
2. EPS Estimate Revisions
Consensus EPS estimates for the fiscal year ending December 2026 have risen by 7.8% over the past three months, underscoring growing analyst confidence in OrthoPediatrics’ financial trajectory.
3. Analyst Price Targets
Wall Street analysts’ average price target for OrthoPediatrics implies a 32.7% upside, reflecting broad bullish sentiment and potential for significant share-price gains if estimates are met.
4. Investor Implications
The combined effect of the Zacks upgrade and the elevated price targets may increase buying pressure, but investors should watch upcoming earnings releases for confirmation of revised projections.